Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Muckle-Wells syndrome: clinical perspectives.

Tran TA.

Open Access Rheumatol. 2017 Jul 11;9:123-129. doi: 10.2147/OARRR.S114447. eCollection 2017. Review.

2.

Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.

Fenini G, Contassot E, French LE.

Front Pharmacol. 2017 May 22;8:278. doi: 10.3389/fphar.2017.00278. eCollection 2017. Review.

3.

A case of cryopyrin-associated periodic syndrome with kidney transplant failure.

Imaizumi R, Ishii Y, Miki K, Kudo S, Murakami T, Koyama I, Nakajima I, Fuchinoue S, Kawaguchi Y, Taniguchi A, Teraoka S.

CEN Case Rep. 2015 May;4(1):1-5. doi: 10.1007/s13730-014-0129-y. Epub 2014 Jun 14.

4.

NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies.

Song L, Pei L, Yao S, Wu Y, Shang Y.

Front Cell Neurosci. 2017 Mar 9;11:63. doi: 10.3389/fncel.2017.00063. eCollection 2017. Review.

5.

Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review.

Finetti M, Omenetti A, Federici S, Caorsi R, Gattorno M.

Orphanet J Rare Dis. 2016 Dec 7;11(1):167. Review.

6.

Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Burns JC, Koné-Paut I, Kuijpers T, Shimizu C, Tremoulet A, Arditi M.

Arthritis Rheumatol. 2017 Feb;69(2):268-276. doi: 10.1002/art.39975. Review. No abstract available.

PMID:
27792871
7.

Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study.

Hirano M, Seguchi J, Yamamura M, Narita A, Okanobu H, Nishikomori R, Heike T, Hosokawa M, Morizane Y, Shiraga F.

J Ophthalmic Inflamm Infect. 2015 Dec;5(1):34. doi: 10.1186/s12348-015-0065-9. Epub 2015 Nov 21.

8.

Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.

Cavalli G, Dinarello CA.

Rheumatology (Oxford). 2015 Dec;54(12):2134-44. doi: 10.1093/rheumatology/kev269. Epub 2015 Jul 23. Review.

9.

Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Lopalco G, Cantarini L, Vitale A, Iannone F, Anelli MG, Andreozzi L, Lapadula G, Galeazzi M, Rigante D.

Mediators Inflamm. 2015;2015:194864. doi: 10.1155/2015/194864. Epub 2015 Feb 16. Review.

10.

Evasion of inflammasome activation by microbial pathogens.

Ulland TK, Ferguson PJ, Sutterwala FS.

J Clin Invest. 2015 Feb;125(2):469-77. doi: 10.1172/JCI75254. Epub 2015 Feb 2. Review.

11.

An expanding role for interleukin-1 blockade from gout to cancer.

Dinarello CA.

Mol Med. 2014 Dec 16;20 Suppl 1:S43-58. doi: 10.2119/molmed.2014.00232. Review.

12.

IL-1 blockade in autoinflammatory syndromes.

Jesus AA, Goldbach-Mansky R.

Annu Rev Med. 2014;65:223-44. doi: 10.1146/annurev-med-061512-150641. Review.

13.

Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.

Kuemmerle-Deschner JB, Haug I.

Ther Adv Musculoskelet Dis. 2013 Dec;5(6):315-29. doi: 10.1177/1759720X13502629. Review.

14.

Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues.

Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M, Compagnone A, Caso P, Frediani B, Galeazzi M, Punzi L, Cantarini L.

Int J Rheumatol. 2013;2013:513782. doi: 10.1155/2013/513782. Epub 2013 Oct 24. Review.

15.

Treating inflammation by blocking interleukin-1 in humans.

Dinarello CA, van der Meer JW.

Semin Immunol. 2013 Dec 15;25(6):469-84. doi: 10.1016/j.smim.2013.10.008. Epub 2013 Nov 23. Review.

16.

The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.

Federici S, Martini A, Gattorno M.

Front Immunol. 2013 Oct 31;4:351. doi: 10.3389/fimmu.2013.00351. Review.

17.

Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.

Sanchez GA, de Jesus AA, Goldbach-Mansky R.

Rheum Dis Clin North Am. 2013 Nov;39(4):701-34. doi: 10.1016/j.rdc.2013.08.001. Epub 2013 Sep 21. Review.

18.

Biological treatments: new weapons in the management of monogenic autoinflammatory disorders.

Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F, Brizi MG, Guerrini S, Patti M, Punzi L, Galeazzi M, Cantarini L.

Mediators Inflamm. 2013;2013:939847. doi: 10.1155/2013/939847. Epub 2013 Jul 21. Review.

19.

Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.

Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, Koetter I, Lohse P, Ummenhofer K, Reess F, Hansmann S, Koitschev A, Deuter C, Bialkowski A, Foell D, Benseler SM.

Arthritis Res Ther. 2013;15(3):R64.

20.

Monogenic autoinflammatory diseases: concept and clinical manifestations.

Almeida de Jesus A, Goldbach-Mansky R.

Clin Immunol. 2013 Jun;147(3):155-74. doi: 10.1016/j.clim.2013.03.016. Epub 2013 Apr 9. Review.

Supplemental Content

Support Center